M
Matthew Wongchenko
Researcher at Genentech
Publications - 79
Citations - 4276
Matthew Wongchenko is an academic researcher from Genentech. The author has contributed to research in topics: Cobimetinib & Vemurafenib. The author has an hindex of 23, co-authored 76 publications receiving 2825 citations. Previous affiliations of Matthew Wongchenko include ARIAD Pharmaceuticals, Inc..
Papers
More filters
Journal ArticleDOI
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Paolo A. Ascierto,Grant A. McArthur,Grant A. McArthur,Brigitte Dréno,Victoria Atkinson,G. Liszkay,Anna Maria Di Giacomo,Mario Mandalà,Lev V. Demidov,Daniil Stroyakovskiy,Luc Thomas,Luis de la Cruz-Merino,Caroline Dutriaux,Claus Garbe,Yibing Yan,Matthew Wongchenko,Ilsung Chang,Jessie J. Hsu,Daniel O. Koralek,Isabelle Rooney,Antoni Ribas,James Larkin +21 more
TL;DR: The safety profile for cobimetinib and vemurafenib was tolerable and manageable, and no new safety signals were observed with longer follow-up.
Journal ArticleDOI
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Tuba N. Gide,Camelia Quek,Alexander M. Menzies,Annie Tasker,Ping Shang,Jeff Holst,Jason Madore,Su Yin Lim,Su Yin Lim,Rebecca Velickovic,Matthew Wongchenko,Yibing Yan,Serigne Lo,Matteo S. Carlino,Alexander Guminski,Robyn P. M. Saw,Robyn P. M. Saw,Angel Pang,Helen M. McGuire,Umaimainthan Palendira,John F. Thompson,John F. Thompson,Helen Rizos,Helen Rizos,Ines Pires da Silva,Marcel Batten,Richard A. Scolyer,Richard A. Scolyer,Georgina V. Long,James S. Wilmott +29 more
TL;DR: An EOMES+CD69+CD45RO+ effector memory T cell phenotype that was significantly more abundant in responders to combined immunotherapy compared with non-responders was associated with longer progression-free survival in patients treated with single agent and greater tumor shrinkage in both treatments.
Journal ArticleDOI
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Jennifer L. McQuade,Carrie R. Daniel,Kenneth R. Hess,Carmen Mak,Daniel Y. Wang,Rajat Rai,John J. Park,Lauren E. Haydu,Christine N. Spencer,Matthew Wongchenko,Stephen R. Lane,Dung Yang Lee,Mathilde Kaper,Meredith Ann McKean,Kathryn E. Beckermann,Samuel M. Rubinstein,Isabelle Rooney,Luna Musib,Nageshwar Budha,Jessie Hao-Ru Hsu,Theodore S. Nowicki,Alexandre Avila,Tomas Haas,Maneka Puligandla,Sandra J. Lee,Shenying Fang,Jennifer A. Wargo,Jeffrey E. Gershenwald,Jeffrey E. Lee,Patrick Hwu,Paul B. Chapman,Jeffrey A. Sosman,Dirk Schadendorf,Jean-Jacques Grob,Keith T. Flaherty,Dana Walker,Yibing Yan,Edward McKenna,Jeffrey J. Legos,Matteo S. Carlino,Matteo S. Carlino,Antoni Ribas,John M. Kirkwood,Georgina V. Long,Douglas B. Johnson,Alexander M. Menzies,Michael A. Davies +46 more
TL;DR: In patients with metastatic melanoma, obesity is associated with improved progression-free survival and overall survival compared with those outcomes in patients with normal BMI, and that this association is mainly seen in male patients treated with targeted or immune therapy.
Journal ArticleDOI
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Sung Bae Kim,Rebecca Dent,Seock-Ah Im,Marc Espié,Sibel Blau,Antoinette R Tan,Steven J Isakoff,Mafalda Oliveira,Cristina Saura,Matthew Wongchenko,Amy V. Kapp,Wai Y. Chan,Stina M. Singel,Daniel J Maslyar,José Baselga,Keun Seok Lee,Hwei Chung Wang,Antoinette R. Tan,Joohyuk Sohn,Michelino De Laurentiis,Laura G. Estévez,Chiun-Sheng Huang,Gilles Romieu,Michel Velez,Rafael Villanueva,Pierfranco Conte,Shaker R. Dakhil,Marc Debled,Antonio Gonzalez Martin,Sara A. Hurvitz,Jee Hyun Kim,Christelle Levy,Pedro Sánchez Rovira,Jae Hong Seo,Vicente Valero,Gregory Vidal,Andrea Wong,Mary Ann K Allison,Robert A. Figlin,David Chan,Shin-Cheh Chen,Yen-Hsun Chen,Melody A. Cobleigh,Filippo de Braud,Luc Dirix,Vincent Hansen,Anne Hardy Bessard,Nicholas Iannotti,Steven J. Isakoff,William E. Lawler,Alvaro Montaño,Mohamad Salkini,Leonard Seigel +52 more
TL;DR: These are the first results supporting AKT-targeted therapy for triple-negative breast cancer and Ipatasertib warrants further investigation for the treatment of triple- negative breast cancer.
Journal ArticleDOI
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells
Maia Vinogradova,Victor S. Gehling,Amy Gustafson,Shilpi Arora,Charles Tindell,Catherine Wilson,Kaylyn E. Williamson,Gulfem D. Guler,Pranoti Gangurde,Wanda Manieri,Jennifer Busby,E. Megan Flynn,Fei Lan,Hyojin Kim,Shobu Odate,Andrea G. Cochran,Yichin Liu,Matthew Wongchenko,Yibin Yang,Tommy K. Cheung,Tobias M. Maile,Ted Lau,Michael R. Costa,Ganapati V. Hegde,Erica L. Jackson,Robert M. Pitti,David Arnott,Christopher M. Bailey,Steve Bellon,Richard T. Cummings,Brian K. Albrecht,Jean-Christophe Harmange,James R. Kiefer,Patrick Trojer,Marie Classon +34 more
TL;DR: Findings show that pretreatment of cancer cells with a KDM5-specific inhibitor results in the ablation of a subpopulation of cancers cells that can serve as the founders for therapeutic relapse.